Optimizing Use of Colistin and Polymyxin B in the Critically Ill

ABSTRACT

Polymyxin B and colistin are being used increasingly for the treatment of infections caused by gram-negative bacteria that are resistant to all other currently available antibiotics. Although the polymyxins have been available in the clinic for around 50 years, they have never been subjected to the drug development procedures required of modern pharmaceuticals. As a result, the available knowledge on the pharmacokinetics (PK), pharmacodynamics (PD), and toxicodynamics (TD) of the polymyxins is limited. Although significant advances have been made in the last 5 years or so, there are still large gaps in our understanding of the PK, PD, and TD, and of the PK/PD and PK/TD relationships. This information is required to generate recommendations on dosage regimens for various categories of critically ill patients. This paper reviews the growing understanding of the pharmacology of the polymyxins and factors that may impact on the optimization of the dose of these antibiotics in critically ill patients.

Colistin - polymyxin B - Acinetobacter - Pseudomonas - clinical pharmacology - critically-ill patients

REFERENCES

• 1 Li J, Nation R L, Milne R W, Turnidge J D, Coulthard K. Evaluation of colistin as an agent against multi-resistant gram-negative bacteria.  Int J Antimicrob Agents. 2005;  25 11-25
• 2 Hancock R E. Peptide antibiotics.  Lancet. 1997;  349 418-422
• 3 Elwood C M, Lucas G D, Muehrcke R C. Acute renal failure associated with sodium colistimethate treatment.  Arch Intern Med. 1966;  118 326-334
• 4 Brown J M, Dorman D C, Roy L P. Acute renal failure due to overdosage of colistin.  Med J Aust. 1970;  2 923-924
• 5 Koch-Weser J, Sidel V W, Federman E B, Kanarek P, Finer D C, Eaton A E. Adverse effects of sodium colistimethate: manifestations and specific reaction rates during 317 courses of therapy.  Ann Intern Med. 1970;  72 857-868
• 6 Duncan D A. Colistin toxicity. Neuromuscular and renal manifestations: two cases treated by hemodialysis.  Minn Med. 1973;  56 31-35
• 7 Bad bugs, no drugs. Infectious Diseases Society of America; 2004. http://www.idsociety.org/badbugsnodrugs.html Accessed November 16, 2007
• 8 Livermore D M. The threat from the pink corner.  Ann Med. 2003;  35 226-234
• 9 Livermore D M. The need for new antibiotics.  Clin Microbiol Infect. 2004;  10(Suppl 4) 1-9
• 10 Talbot G H, Bradley J, Edwards Jr J E, Gilbert D, Scheld M, Bartlett J G. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America.  Clin Infect Dis. 2006;  42 657-668
• 11 Gales A C, Jones R N, Sader H S. Global assessment of the antimicrobial activity of polymyxin B against 54731 clinical isolates of gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004).  Clin Microbiol Infect. 2006;  12 315-321
• 12 Sueke H, Marsh H, Dhital A. Using intrathecal colistin for multidrug resistant shunt infection.  Br J Neurosurg. 2005;  19 51-52
• 13 Reina R, Estenssoro E, Saenz G et al.. Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study.  Intensive Care Med. 2005;  31 1058-1065
• 14 Quinn A L, Parada J P, Belmares J, O'Keefe J P. Intrathecal colistin and sterilization of resistant Pseudomonas aeruginosa shunt infection.  Ann Pharmacother. 2005;  39 949-952
• 15 Obritsch M D, Fish D N, Maclaren R, Jung R. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options.  Pharmacotherapy. 2005;  25 1353-1364
• 16 Mubareka S, Rubinstein E. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant gram-negative bacteria in patients without cystic fibrosis.  Crit Care. 2005;  9 29-30
• 17 Michalopoulos A, Kasiakou S, Rosmarakis E, Falagas M. Cure of multidrug-resistant Acinetobacter baumannii bacteraemia with continuous intravenous infusion of colistin.  Scand J Infect Dis. 2005;  37 142-145
• 18 Michalopoulos A S, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas M E. Colistin treatment in patients with ICU-acquired infections caused by multiresistant gram-negative bacteria: the renaissance of an old antibiotic.  Clin Microbiol Infect. 2005;  11 115-121
• 19 Katragkou A, Roilides E. Successful treatment of multidrug-resistant Acinetobacter baumannii central nervous system infections with colistin.  J Clin Microbiol. 2005;  43 4916-4917
• 20 Kasiakou S K, Rafailidis P I, Liaropoulos K, Falagas M E. Cure of post-traumatic recurrent multiresistant gram-negative rod meningitis with intraventricular colistin.  J Infect. 2005;  50 348-352
• 21 Gump W C, Walsh J W. Intrathecal colistin for treatment of highly resistant Pseudomonas ventriculitis: case report and review of the literature.  J Neurosurg. 2005;  102 915-917
• 22 Falagas M E, Bliziotis I A, Kasiakou S K, Samonis G, Athanassopoulou P, Michalopoulos A. Outcome of infections due to pandrug-resistant (PDR) gram-negative bacteria.  BMC Infect Dis. 2005;  5 24
• 23 Falagas M E, Rizos M, Bliziotis I A, Rellos K, Kasiakou S K, Michalopoulos A. Toxicity after prolonged (more than four weeks) administration of intravenous colistin.  BMC Infect Dis. 2005;  5 1
• 24 Bukhary Z, Mahmood W, Al-Khani A, Al-Abdely H M. Treatment of nosocomial meningitis due to a multidrug resistant Acinetobacter baumannii with intraventricular colistin.  Saudi Med J. 2005;  26 656-658
• 25 Berlana D, Llop J M, Fort E, Badia M B, Jodar R. Use of colistin in the treatment of multiple-drug-resistant gram-negative infections.  Am J Health Syst Pharm. 2005;  62 39-47
• 26 Bratu S, Tolaney P, Karumudi U et al.. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents.  J Antimicrob Chemother. 2005;  56 128-132
• 27 Bratu S, Quale J, Cebular S, Heddurshetti R, Landman D. Multidrug-resistant Pseudomonas aeruginosa in Brooklyn, New York: molecular epidemiology and in vitro activity of polymyxin B.  Eur J Clin Microbiol Infect Dis. 2005;  24 196-201
• 28 Sarria J C, Angulo-Pernett F, Kimbrough R C, McVay C S, Vidal A M. Use of intravenous polymyxin B during continuous venovenous hemodialysis.  Eur J Clin Microbiol Infect Dis. 2004;  23 340-341
• 29 Falagas M E, Kasiakou S K. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections.  Clin Infect Dis. 2005;  40 1333-1341
• 30 Li J, Nation R L, Turnidge J D et al.. Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections.  Lancet Infect Dis. 2006;  6 589-601
• 31 Bergen P J, Li J, Rayner C R, Nation R L. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa .  Antimicrob Agents Chemother. 2006;  50 1953-1958
• 32 Evans M E, Feola D J, Rapp R P. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria.  Ann Pharmacother. 1999;  33 960-967
• 33 Falagas M E, Kasiakou S K. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies.  Crit Care. 2006;  10 R27
• 34 Conway S P, Etherington C, Munday J, Goldman M H, Strong J J, Wootton M. Safety and tolerability of bolus intravenous colistin in acute respiratory exacerbations in adults with cystic fibrosis.  Ann Pharmacother. 2000;  34 1238-1242
• 35 Conway S P, Pond M N, Watson A, Etherington C, Robey H L, Goldman M H. Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis.  Thorax. 1997;  52 987-993
• 36 Conway S P, Brownlee K G, Denton M, Peckham D G. Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis.  Am J Respir Med. 2003;  2 321-332
• 37 Littlewood J M, Koch C, Lambert P A et al.. A ten year review of Colomycin.  Respir Med. 2000;  94 632-640
• 38 Ledson M J, Gallagher M J, Cowperthwaite C, Convery R P, Walshaw M J. Four years' experience of intravenous colomycin in an adult cystic fibrosis unit.  Eur Respir J. 1998;  12 592-594
• 39 Etherington C, Conway S P, Peckham D G, Bosomworth M. Urinary N-acetyl -b-D-glucosaminidase [NAG] in adults with CF: a marker of nephrotoxicity?.  J Cyst Fibros. 2004;  3(Suppl 1) 549 (abstract 180)
• 40 Al-Aloul M, Miller H, Alapati S, Stockton P A, Ledson M J, Walshaw M J. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use.  Pediatr Pulmonol. 2005;  39 15-20
• 41 Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez F J et al.. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP.  Clin Infect Dis. 2003;  36 1111-1118
• 42 Reed M D, Stern R C, O'Riordan M A, Blumer J L. The pharmacokinetics of colistin in patients with cystic fibrosis.  J Clin Pharmacol. 2001;  41 645-654
• 43 Coly-Mycin M. Parenteral [package insert]. Bristol, TN; Monarch Pharmaceuticals 2005
• 44 Colomycin injection [summary of product characteristics]. Kent, UK; Forest Laboratories UK Limited 2004
• 45 Gales A C, Reis A O, Jones R N. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines.  J Clin Microbiol. 2001;  39 183-190
• 46 Clinical and Laboratory Standards Institute .Performance standards for antimicrobial susceptibility testing; fifteenth information supplement (M100-S15). Wayne, PA; Clinical Laboratory Standards Institute 2005
• 47 Li J, Milne R W, Nation R L, Turnidge J D, Coulthard K. Stability of colistin and colistin methanesulfonate in aqueous media and plasma studied by high-performance liquid chromatography.  Antimicrob Agents Chemother. 2003;  47 1364-1370
• 48 Li J, Coulthard K, Milne R et al.. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis.  J Antimicrob Chemother. 2003;  52 987-992
• 49 Li J, Milne R W, Nation R L, Turnidge J D, Smeaton T C, Coulthard K. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate.  J Antimicrob Chemother. 2004;  53 837-840
• 50 Li J, Rayner C R, Nation R L et al.. Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration.  Antimicrob Agents Chemother. 2005;  49 4814-4815
• 51 Li J, Rayner C R, Nation R L, Owen R J, Tan K E, Spelman D. Hetero-resistance to colistin in multidrug-resistant Acinetobacter baumannii .  Antimicrob Agents Chemother. 2006;  50 2946-2950
• 52 Ebert S C, Craig W A. Pharmacodynamic properties of antibiotics: application to drug monitoring and dosage regimen design.  Infect Control Hosp Epidemiol. 1990;  11 319-326
• 53 Catchpole C R, Andrews J M, Brenwald N, Wise R. A reassessment of the in-vitro activity of colistin sulphomethate sodium.  J Antimicrob Chemother. 1997;  39 255-260
• 54 Tam V H, Schilling A N, Vo G et al.. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa .  Antimicrob Agents Chemother. 2005;  49 3624-3630
• 55 Owen R J, Li J, Nation R L, Spelman D. In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates.  J Antimicrob Chemother. 2007;  59 473-477
• 56 Li J, Turnidge J, Milne R, Nation R L, Coulthard K. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis.  Antimicrob Agents Chemother. 2001;  45 781-785
• 57 Bergen P J, Li J, Nation R L, Turnidge J D, Coulthard K, Milne R W. Is once-daily dosing best for colistin against Pseudomonas aeruginosa? In: Proceedings of the Australian Society for Antimicrobials. Melbourne, Australia; 2007
• 58 Tan C H, Li J, Nation R L. Pharmacodynamics of colistin against Acinetobacter baumannii in an in vitro PD model and development of resistance. In: Proceedings of the Australian Society for Antimicrobials. Sydney, Australia; 2006
• 59 Gunderson B W, Ibrahim K H, Hovde L B, Fromm T L, Reed M D, Rotschafer J C. Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model.  Antimicrob Agents Chemother. 2003;  47 905-909
• 60 Zhanel G G, Craig W A. Pharmacokinetic contributions to postantibiotic effects: focus on aminoglycosides.  Clin Pharmacokinet. 1994;  27 377-392
• 61 Montero A, Ariza J, Corbella X et al.. Efficacy of colistin versus beta-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii .  Antimicrob Agents Chemother. 2002;  46 1946-1952
• 62 Montero A, Ariza J, Corbella X et al.. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model.  J Antimicrob Chemother. 2004;  54 1085-1091
• 63 Mahmood I. Allometric issues in drug development.  J Pharm Sci. 1999;  88 1101-1106
• 64 Gales A C, Jones R N, Sader H S. Global assessment of the antimicrobial activity of polymyxin B against 54731 clinical isolates of gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004).  Clin Microbiol Infect. 2006;  12 315-321
• 65 Gilad J, Eskira S, Riesenberg K, Schlaeffer F, Hyam E, Borer A. Emergence of nosocomial colistin-resistant Acinetobacter baumannii. In: 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington DC; American Society for Microbiology 2005
• 66 Antoniadou A, Kontopidou F V, Poulakou G et al.. Emerging Colimycin resistant strains of Klebsiella pneumoniae from intensive care unit patients. In: 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington DC; American Society for Microbiology 2005
• 67 Li J, Nation R L. Old polymyxins are back, is resistance close?.  Clin Infect Dis. 2006;  43 663-664
• 68 Craig W A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.  Clin Infect Dis. 1998;  26 1-10 quiz 1-2
• 69 Ambrose P G, Bhavnani S M, Rubino C M et al.. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore.  Clin Infect Dis. 2007;  44 79-86
• 70 Li J, Milne R W, Nation R L, Turnidge J D, Coulthard K, Johnson D W. A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography.  J Chromatogr B Biomed Sci Appl. 2001;  761 167-175
• 71 Li J, Milne R W, Nation R L, Turnidge J D, Coulthard K, Valentine J. Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography.  Antimicrob Agents Chemother. 2002;  46 3304-3307
• 72 Li J, Milne R W, Nation R L, Turnidge J D, Smeaton T C, Coulthard K. Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration.  Antimicrob Agents Chemother. 2003;  47 1766-1770
• 73 Coly-Mycin M. Parenteral [package insert]. Mosman, NSW, Australia; Link Medical Products Pty Ltd. 2006
• 74 Uchino S, Kellum J A, Bellomo R et al.. Acute renal failure in critically ill patients: a multinational, multicenter study.  JAMA. 2005;  294 813-818
• 75 Trotman R L, Williamson J C, Shoemaker D M, Salzer W L. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy.  Clin Infect Dis. 2005;  41 1159-1166
• 76 Goodwin N J, Friedman E A. The effects of renal impairment, peritoneal dialysis, and hemodialysis on serum sodium colistimethate levels.  Ann Intern Med. 1968;  68 984-994
• 77 Jimenez-Mejias M E, Becerril B, Marquez-Rivas F J, Pichardo C, Cuberos L, Pachon J. Successful treatment of multidrug-resistant Acinetobacter baumannii meningitis with intravenous colistin sulfomethate sodium.  Eur J Clin Microbiol Infect Dis. 2000;  19 970-971
• 78 Jimenez-Mejias M E, Pichardo-Guerrero C, Marquez-Rivas F J, Martin-Lozano D, Prados T, Pachon J. Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis.  Eur J Clin Microbiol Infect Dis. 2002;  21 212-214